Suven Life Sciences | Business Upturn

Latest Articles

Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder

Corporates · Dec 11, 2025

blank

Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107

Corporates · Jan 8, 2025

By Aditya Bhagchandani

blank

Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder

Corporates · Sep 18, 2024

blank

Suven Life Sciences announces FDA acceptance of Investigational New Drug

Business · Aug 27, 2024

blank

Suven Life Sciences shares fall 4% after reporting loss in Q4

Stock Market · May 7, 2024

By Aditya Bhagchandani